Attached files

file filename
EX-99.1 - EX-99.1 - Assertio Therapeutics, Inca16-18708_8ex99d1.htm
EX-10.1 - EX-10.1 - Assertio Therapeutics, Inca16-18708_8ex10d1.htm
EX-3.2 - EX-3.2 - Assertio Therapeutics, Inca16-18708_8ex3d2.htm
8-K - 8-K - Assertio Therapeutics, Inca16-18708_88k.htm

Exhibit 3.1

 

AMENDMENT NO. 1 TO THE

 

AMENDED AND RESTATED BYLAWS

 

OF

 

Depomed, Inc.

a California corporation

 

Dated: October 17, 2016.

 

The Amended and Restated Bylaws of Depomed, Inc., a California corporation (the “Corporation”), pursuant to Section 42 thereof, are amended as set forth below:

 

1.         Section 5(c) of the Amended and Restated Bylaws of the Corporation is amended and restated in its entirety to read as follows:

 

(c)        To be timely, a shareholder’s notice shall be delivered to the Secretary at the principal executive offices of the corporation not less than 120 or more than 150 days prior to the first anniversary (the “Anniversary”) of the date on which the corporation first mailed its proxy materials for the preceding year’s annual meeting of shareholders; provided, however, that if the date of the annual meeting is advanced more than 30 days prior to or delayed by more than 30 days after the anniversary of the preceding year’s annual meeting, notice by the shareholder to be timely must be so delivered not later than the close of business on the later of the 120th day prior to such annual meeting, or the 10th day following the day on which public announcement of the date of such meeting is first made; provided, further, that in the case of the corporation’s 2017 annual meeting of shareholders, to be timely, a shareholder’s notice shall be delivered to the Secretary at the principal executive offices of the corporation not earlier than March 15, 2017 and not later than April 15, 2017.

 

2.         Except as specifically amended herein, the Amended and Restated Bylaws of the Corporation shall remain unchanged and in full force and effect.